EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Julia Kozlitina iD, Silvia Sookoian iD

Liver International · 2025-03 · 45 (3)

DOI: 10.1111/liv.16123 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 07.10.2024. Verfasst von Julia Kozlitina und 1 weiteren Autor:innen. Beteiligte Einrichtung: Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Lipase, Membrane Proteins, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Tecnológica Argentina, FONCyT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) has increased exponentially over the past three decades, in parallel with the global rise in obesity and type 2 diabetes. It is currently the most common cause of liver‐related morbidity and mortality. Although obesity has been identified as a key factor in the increased prevalence of MASLD, individual differences in susceptibility are significantly influenced by genetic factors. PNPLA3 I148M (rs738409 C>G) is the variant with the greatest impact on the risk of developing progressive MASLD and likely other forms of steatotic liver disease. This variant is prevalent across the globe, with the risk allele (G) frequency exhibiting considerable variation. Here, we review the contribution of PNPLA3 I148M to global burden and regional differences in MASLD prevalence, focusing on recent evidence emerging from population‐based sequencing studies and prevalence assessments. We calculated the population attributable fraction (PAF) as a means of quantifying the impact of the variant on MASLD. Furthermore, we employ quantitative trait locus (QTL) analysis to ascertain the associations between rs738409 and a range of phenotypic traits. This analysis suggests that these QTLs may underpin pleiotropic effects on extrahepatic traits. Finally, we outline potential avenues for further research and identify key areas for investigation in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipaseMembrane ProteinsFatty LiverNon-alcoholic Fatty Liver DiseaseHumansGenetic Predisposition to DiseasePrevalenceQuantitative Trait LociGlobal HealthPolymorphism, Single NucleotideAcyltransferasesPhospholipases A2, Calcium-Independent

Stichwörter der Autor:innen

PNPLA3HSD17B13MASHMASLDgeneticsrs6006460rs738409

Substanzen

PNPLA3 protein, humanLipaseMembrane ProteinsAcyltransferasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
  • Clinical and Molecular Hepatology, Translational Health Research Center (CENITRES), Maimónides University, Buenos Aires, Argentina.

ORCID-Profile: Julia Kozlitina, Silvia Sookoian

Förderung

  • Agencia Nacional de Promoción Científica y Tecnológica Argentina, FONCyT

Zitieren

APA

Kozlitina, J., & Sookoian, S. (2025). Global Epidemiological Impact of PNPLA3 I148M on Liver Disease. Liver International, 45(3). https://doi.org/10.1111/liv.16123

Vancouver

Kozlitina J, Sookoian S. Global Epidemiological Impact of PNPLA3 I148M on Liver Disease. Liver International. 2025;45(3). doi:10.1111/liv.16123

BibTeX
@article{Kozlitina2025,
  author = {Kozlitina, Julia and Sookoian, Silvia},
  title = {Global Epidemiological Impact of PNPLA3 I148M on Liver Disease},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1111/liv.16123}
}
Kostenlos starten →